ProCE Banner Activity

LUN 14-179: Phase II Trial of Concurrent Chemoradiation Followed by Consolidation Pembrolizumab in Unresectable Stage III NSCLC

Slideset Download
Conference Coverage
In this phase II trial, consolidation pembrolizumab improved time to metastatic disease or death and PFS compared with historical outcomes.

Released: June 05, 2018

Expiration: June 04, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Astellas Text

AstraZeneca

Celgene

Eisai

Genentech TEXT Only

Janssen

Merck Oncology

Seagen